Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Public ClinicalTrials.gov record NCT00907296. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail
Study identification
- NCT ID
- NCT00907296
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 402 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Romosozumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2009
- Primary completion
- Mar 5, 2012
- Completion
- May 9, 2013
- Last update posted
- Sep 21, 2022
2009 – 2013
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Aurora | Colorado | 80012 | — |
| Research Site | Denver | Colorado | 80204 | — |
| Research Site | Jacksonville | Florida | 32209 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Brooklyn | New York | 11220 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Altoona | Pennsylvania | 16602 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Columbia | South Carolina | 29203 | — |
| Research Site | Sandy City | Utah | 84070 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00907296, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2022 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00907296 live on ClinicalTrials.gov.